Skip to main content

Valsartan Recall Urges Some Drug Makers To Increase Prices

Valsartan Recall Urges Some Drug Makers To Increase Prices

When two generic companies manufacturing valsartan recalled hundreds of lots of the blood-pressure medicine last July, Alembic Pharmaceuticals was unaffected by the recall and saw the perfect opportunity to increase prices.  Teva Pharmaceutical and Prinston Pharmaceutical recalled the medications after testing indicated traces of carcinogens in their medications. Making a smart move, Alembic tripled the price of 17 of its own valsartan formulations. According to the data from a healthcare analytics firm, th

Introduction

When two generic companies manufacturing valsartan recalled hundreds of lots of the blood-pressure medicine last July, Alembic Pharmaceuticals was unaffected by the recall and saw the perfect opportunity to increase prices.

Teva Pharmaceutical and Prinston Pharmaceutical recalled the medications after testing indicated traces of carcinogens in their medications. Making a smart move, Alembic tripled the price of 17 of its own valsartan formulations. According to the data from a healthcare analytics firm, the price hikes ranged from 329% to 469%. The Wall Street Journal stated the prices for McCleods Pharmaceuticals’ valsartan products surged as much as 305%. The price hikes affected those consumers who have prescription drug coverage, as they would get high co-pays and premiums next year when insurance companies respond to the price hikes. It is also bad news for those without coverage, as they will not be able to afford costlier medications, and they might compromise on their ongoing treatment altogether by controlling the medication.

Several individuals have already filed valsartan lawsuits seeking fair compensation for their cancer allegedly caused due to N-Nitrosodimethylamine (NDMA) or  N-nitrosodiethylamine (NDEA) contamination in the blood pressure drug. The U.S. Judicial Panel on Multidistrict Litigation last week heard oral arguments on the motion, to centralize product liability claims linked to valsartan recall before a single federal judge for coordinated discovery and other pretrial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.